Amrita Nallathambi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amrita Nallathambi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Brian Kuhlman
Department of Biochemistry and Biophysics University of North Carolina School of Medicine Chapel Hill North Carolina USA
3 shared publications - Tomoaki Kinjo
Department of Biochemistry and Biophysics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
3 shared publications - Nicholas Z. Randolph
Department of Biochemistry and Biophysics, University of North Carolina School of Medicine, Chapel Hill, NC 27599
2 shared publications - Odessa J. Goudy
Department of Biochemistry and Biophysics, University of North Carolina School of Medicine, Chapel Hill, NC 27599
2 shared publications - Albert A. Bowers
University of North Carolina at Chapel Hill
1 shared publication - Avery K. Huber
Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
1 shared publication
Latest Publications
- Open Access
Enhancing ML-based binder design with high-throughput screening: a comparison of mRNA and yeast display technologies
Recent advances in machine learning (ML)-based protein design methods have enabled the rapid in silico generation of large libraries of miniprotein binders with minimal manual input. While computational design capacity has scaled rapidly, experimental validation methods have lagged, creating a bottleneck in binder discovery pipelines. Here, we apply mRNA display to screen an ML-designed miniprotein binder library and directly compare its performance with the more widely used yeast surface display platform using a single shared DNA library. We screened 2,009 designs targeting the platelet receptor TLT-1 and 3,159 designs targeting the immune receptor B7-H3 across both platforms. While both selection methods reliably identified functional binders, we found that mRNA display preferentially enriched binders with slower dissociation rates. In addition, mRNA display achieved higher library coverage than yeast display, likely rescuing functional designs that are penalized in a cell-based expression system. Biophysical characterization of selected binders from both platforms revealed strong binding affinities and high thermal stabilities. These results showcase the power of integrating ML-based computational design tools with rapid in vitro selection technologies, providing a scalable framework for therapeutic miniprotein discovery. IMPORTANCE: Miniprotein binders offer major advantages as next-generation therapeutics, including small size, high stability, and efficient production. In this work, we conduct a side-by-side comparison of mRNA and yeast display as platforms for high-throughput evaluation of de novo miniprotein binders. The binders generated here serve as starting points for therapeutics targeting TLT-1 or B7-H3, two clinically relevant molecules.
Open AccessEnhancing ML-based binder design with high-throughput screening: a comparison of mRNA and yeast display technologies
Recent advances in machine learning (ML)-based protein design methods have enabled the rapid in silico generation of large libraries of miniprotein binders with minimal manual input. While computational design capacity has scaled rapidly, experimental validation methods have lagged, creating a bottleneck in binder discovery pipelines. Here, we apply mRNA display to screen an ML-designed miniprotein binder library and directly compare its performance with the more widely used yeast surface display platform using a single shared DNA library. We screened 2,009 designs targeting the platelet receptor TLT-1 and 3,159 designs targeting the immune receptor B7-H3 across both platforms. While both selection methods reliably identified functional binders, we found that mRNA display preferentially enriched binders with slower dissociation rates. In addition, mRNA display achieved higher library coverage than yeast display, likely rescuing functional designs that are penalized in a cell-based expression system. Biophysical characterization of selected binders from both platforms revealed strong binding affinities and high thermal stabilities. These results showcase the power of integrating ML-based computational design tools with rapid in vitro selection technologies, providing a scalable framework for therapeutic miniprotein discovery. IMPORTANCE: Miniprotein binders offer major advantages as next-generation therapeutics, including small size, high stability, and efficient production. In this work, we conduct a side-by-side comparison of mRNA and yeast display as platforms for high-throughput evaluation of de novo miniprotein binders. The binders generated here serve as starting points for therapeutics targeting TLT-1 or B7-H3, two clinically relevant molecules.
- Open Access
- 30 November 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (49)
In silico evolution of autoinhibitory domains for a PD-L1 antagonist using deep learning models
There has been considerable progress in the development of computational methods for designing protein–protein interactions, but engineering high-affinity binders without extensive screening and maturation remains challenging. Here, we test a protein design pipeline that uses iterative rounds of deep learning (DL)-based structure prediction (AlphaFold2) and sequence optimization (ProteinMPNN) to design autoinhibitory domains (AiDs) for a PD-L1 antagonist. With the goal of creating an anticancer agent that is inactive until reaching the tumor environment, we sought to create autoinhibited (or masked) forms of the PD-L1 antagonist that can be unmasked by tumor-enriched proteases. Twenty-three de novo designed AiDs, varying in length and topology, were fused to the antagonist with a protease-sensitive linker, and binding to PD-L1 was measured with and without protease treatment. Nine of the fusion proteins demonstrated conditional binding to PD-L1, and the top-performing AiDs were selected for further characterization as single-domain proteins. Without any experimental affinity maturation, four of the AiDs bind to the PD-L1 antagonist with equilibrium dissociation constants (K D s) below 150 nM, with the lowest K D equal to 0.9 nM. Our study demonstrates that DL-based protein modeling can be used to rapidly generate high-affinity protein binders.
- 30 November 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (49)
Open AccessIn silico evolution of autoinhibitory domains for a PD-L1 antagonist using deep learning models
There has been considerable progress in the development of computational methods for designing protein–protein interactions, but engineering high-affinity binders without extensive screening and maturation remains challenging. Here, we test a protein design pipeline that uses iterative rounds of deep learning (DL)-based structure prediction (AlphaFold2) and sequence optimization (ProteinMPNN) to design autoinhibitory domains (AiDs) for a PD-L1 antagonist. With the goal of creating an anticancer agent that is inactive until reaching the tumor environment, we sought to create autoinhibited (or masked) forms of the PD-L1 antagonist that can be unmasked by tumor-enriched proteases. Twenty-three de novo designed AiDs, varying in length and topology, were fused to the antagonist with a protease-sensitive linker, and binding to PD-L1 was measured with and without protease treatment. Nine of the fusion proteins demonstrated conditional binding to PD-L1, and the top-performing AiDs were selected for further characterization as single-domain proteins. Without any experimental affinity maturation, four of the AiDs bind to the PD-L1 antagonist with equilibrium dissociation constants (K D s) below 150 nM, with the lowest K D equal to 0.9 nM. Our study demonstrates that DL-based protein modeling can be used to rapidly generate high-affinity protein binders.
- 15 August 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (34) , 18773-18777
Characterizing Protonation-Coupled Conformational Ensembles in RNA via pH-Differential Mutational Profiling with DMS Probing
RNA molecules undergo conformational transitions in response to cellular and environmental stimuli. Site-specific protonation, a fundamental chemical property, can alter the conformational landscape of RNA to regulate their functions. However, characterizing protonation-coupled RNA conformational ensembles on a large scale remains challenging. Here, we present pH-differential mutational profiling (PD-MaP) with dimethyl sulfate probing for high-throughput detection of protonation-coupled conformational ensembles in RNA. We demonstrated this approach on microRNA-21 precursor (pre-miR-21) and recapitulated a previously discovered A+-G-coupled conformational ensemble. Additionally, we identified a secondary protonation event involving an A+-C mismatch. We validated the occurrence of both protonation-coupled ensembles in pre-miR-21 using NMR relaxation dispersion spectroscopy. Furthermore, the application of PD-MaP on a library of well-annotated human primary microRNAs uncovered widespread protonation-coupled conformational ensembles, suggesting their potentially broad functions in biology.
- 15 August 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (34) , 18773-18777
Characterizing Protonation-Coupled Conformational Ensembles in RNA via pH-Differential Mutational Profiling with DMS Probing
RNA molecules undergo conformational transitions in response to cellular and environmental stimuli. Site-specific protonation, a fundamental chemical property, can alter the conformational landscape of RNA to regulate their functions. However, characterizing protonation-coupled RNA conformational ensembles on a large scale remains challenging. Here, we present pH-differential mutational profiling (PD-MaP) with dimethyl sulfate probing for high-throughput detection of protonation-coupled conformational ensembles in RNA. We demonstrated this approach on microRNA-21 precursor (pre-miR-21) and recapitulated a previously discovered A+-G-coupled conformational ensemble. Additionally, we identified a secondary protonation event involving an A+-C mismatch. We validated the occurrence of both protonation-coupled ensembles in pre-miR-21 using NMR relaxation dispersion spectroscopy. Furthermore, the application of PD-MaP on a library of well-annotated human primary microRNAs uncovered widespread protonation-coupled conformational ensembles, suggesting their potentially broad functions in biology.
- Open Access
In silico evolution of protein binders with deep learning models for structure prediction and sequence design
There has been considerable progress in the development of computational methods for designing protein-protein interactions, but engineering high-affinity binders without extensive screening and maturation remains challenging. Here, we test a protein design pipeline that uses iterative rounds of deep learning (DL)-based structure prediction (AlphaFold2) and sequence optimization (ProteinMPNN) to design autoinhibitory domains (AiDs) for a PD-L1 antagonist. Inspired by recent advances in therapeutic design, we sought to create autoinhibited (or masked) forms of the antagonist that can be conditionally activated by proteases. Twenty-three de novo designed AiDs, varying in length and topology, were fused to the antagonist with a protease sensitive linker, and binding to PD-L1 was tested with and without protease treatment. Nine of the fusion proteins demonstrated conditional binding to PD-L1 and the top performing AiDs were selected for further characterization as single domain proteins. Without any experimental affinity maturation, four of the AiDs bind to the PD-L1 antagonist with equilibrium dissociation constants (K D s) below 150 nM, with the lowest K D equal to 0.9 nM. Our study demonstrates that DL-based protein modeling can be used to rapidly generate high affinity protein binders. Significance statement: Protein-protein interactions are critical to most processes in biology, and improved methods for designing protein binders will enable the creation of new research reagents, diagnostics, and therapeutics. In this study, we show that a deep learning-based method for protein design can create high-affinity protein binders without the need for extensive screening or affinity maturation.
Open AccessIn silico evolution of protein binders with deep learning models for structure prediction and sequence design
There has been considerable progress in the development of computational methods for designing protein-protein interactions, but engineering high-affinity binders without extensive screening and maturation remains challenging. Here, we test a protein design pipeline that uses iterative rounds of deep learning (DL)-based structure prediction (AlphaFold2) and sequence optimization (ProteinMPNN) to design autoinhibitory domains (AiDs) for a PD-L1 antagonist. Inspired by recent advances in therapeutic design, we sought to create autoinhibited (or masked) forms of the antagonist that can be conditionally activated by proteases. Twenty-three de novo designed AiDs, varying in length and topology, were fused to the antagonist with a protease sensitive linker, and binding to PD-L1 was tested with and without protease treatment. Nine of the fusion proteins demonstrated conditional binding to PD-L1 and the top performing AiDs were selected for further characterization as single domain proteins. Without any experimental affinity maturation, four of the AiDs bind to the PD-L1 antagonist with equilibrium dissociation constants (K D s) below 150 nM, with the lowest K D equal to 0.9 nM. Our study demonstrates that DL-based protein modeling can be used to rapidly generate high affinity protein binders. Significance statement: Protein-protein interactions are critical to most processes in biology, and improved methods for designing protein binders will enable the creation of new research reagents, diagnostics, and therapeutics. In this study, we show that a deep learning-based method for protein design can create high-affinity protein binders without the need for extensive screening or affinity maturation.